Medical Care
Global Adeno Associated Virus Vector CDMO Market Research Report 2025
- Jul 08, 25
- ID: 362300
- Pages: 81
- Figures: 84
- Views: 2
The global market for Adeno Associated Virus Vector CDMO was valued at US$ 1650 million in the year 2024 and is projected to reach a revised size of US$ 5501 million by 2031, growing at a CAGR of 18.2% during the forecast period.
AAV vector CDMOs (Contract Development and Manufacturing Organizations) are specialized service providers that offer comprehensive development and manufacturing support for adeno-associated virus (AAV) vectors used in gene therapy. These companies deliver end-to-end services including plasmid production, process development, upstream and downstream manufacturing, analytical testing, formulation, fill-finish, and regulatory support under cGMP conditions. Given the complexity and regulatory demands of AAV-based therapeutics, CDMOs play a pivotal role in accelerating the transition of gene therapy products from research to clinical and commercial stages by offering scalable, compliant, and high-quality manufacturing solutions.
North American market for Adeno Associated Virus Vector CDMO is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for Adeno Associated Virus Vector CDMO is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The global market for Adeno Associated Virus Vector CDMO in Pharmaceutical and Biopharmaceutical Companies is estimated to increase from $ million in 2024 to $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global companies of Adeno Associated Virus Vector CDMO include Thermo Fisher Scientific, Oxford BioMedica, Lonza, GENEWIZ, Revvity, VectorBuilder, OBIO Technology, Takara Bio, GenScript Biotech, Gene Chem, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Adeno Associated Virus Vector CDMO, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Adeno Associated Virus Vector CDMO.
The Adeno Associated Virus Vector CDMO market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Adeno Associated Virus Vector CDMO market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Adeno Associated Virus Vector CDMO companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Thermo Fisher Scientific
Oxford BioMedica
Lonza
GENEWIZ
Revvity
VectorBuilder
OBIO Technology
Takara Bio
GenScript Biotech
Gene Chem
Geno Meditech
PackGene Biotech
VIROVEK
Segment by Type
Clinical
Preclinical
Commerical
Segment by Application
Pharmaceutical and Biopharmaceutical Companies
Academics and Research Institutes
Others
By Region
North America
U.S.
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia & New Zealand
Europe
Germany
France
U.K.
Italy
Ireland
Russia
Rest of Europe
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Israel
United Arab Emirates (UAE)
Saudi Arabia
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Adeno Associated Virus Vector CDMO company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
AAV vector CDMOs (Contract Development and Manufacturing Organizations) are specialized service providers that offer comprehensive development and manufacturing support for adeno-associated virus (AAV) vectors used in gene therapy. These companies deliver end-to-end services including plasmid production, process development, upstream and downstream manufacturing, analytical testing, formulation, fill-finish, and regulatory support under cGMP conditions. Given the complexity and regulatory demands of AAV-based therapeutics, CDMOs play a pivotal role in accelerating the transition of gene therapy products from research to clinical and commercial stages by offering scalable, compliant, and high-quality manufacturing solutions.
North American market for Adeno Associated Virus Vector CDMO is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for Adeno Associated Virus Vector CDMO is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The global market for Adeno Associated Virus Vector CDMO in Pharmaceutical and Biopharmaceutical Companies is estimated to increase from $ million in 2024 to $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global companies of Adeno Associated Virus Vector CDMO include Thermo Fisher Scientific, Oxford BioMedica, Lonza, GENEWIZ, Revvity, VectorBuilder, OBIO Technology, Takara Bio, GenScript Biotech, Gene Chem, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Adeno Associated Virus Vector CDMO, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Adeno Associated Virus Vector CDMO.
The Adeno Associated Virus Vector CDMO market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Adeno Associated Virus Vector CDMO market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Adeno Associated Virus Vector CDMO companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Thermo Fisher Scientific
Oxford BioMedica
Lonza
GENEWIZ
Revvity
VectorBuilder
OBIO Technology
Takara Bio
GenScript Biotech
Gene Chem
Geno Meditech
PackGene Biotech
VIROVEK
Segment by Type
Clinical
Preclinical
Commerical
Segment by Application
Pharmaceutical and Biopharmaceutical Companies
Academics and Research Institutes
Others
By Region
North America
U.S.
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia & New Zealand
Europe
Germany
France
U.K.
Italy
Ireland
Russia
Rest of Europe
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Israel
United Arab Emirates (UAE)
Saudi Arabia
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Adeno Associated Virus Vector CDMO company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Adeno Associated Virus Vector CDMO Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 Clinical
1.2.3 Preclinical
1.2.4 Commerical
1.3 Market by Application
1.3.1 Global Adeno Associated Virus Vector CDMO Market Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Pharmaceutical and Biopharmaceutical Companies
1.3.3 Academics and Research Institutes
1.3.4 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Adeno Associated Virus Vector CDMO Market Perspective (2020-2031)
2.2 Global Adeno Associated Virus Vector CDMO Growth Trends by Region
2.2.1 Global Adeno Associated Virus Vector CDMO Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 Adeno Associated Virus Vector CDMO Historic Market Size by Region (2020-2025)
2.2.3 Adeno Associated Virus Vector CDMO Forecasted Market Size by Region (2026-2031)
2.3 Adeno Associated Virus Vector CDMO Market Dynamics
2.3.1 Adeno Associated Virus Vector CDMO Industry Trends
2.3.2 Adeno Associated Virus Vector CDMO Market Drivers
2.3.3 Adeno Associated Virus Vector CDMO Market Challenges
2.3.4 Adeno Associated Virus Vector CDMO Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Adeno Associated Virus Vector CDMO Players by Revenue
3.1.1 Global Top Adeno Associated Virus Vector CDMO Players by Revenue (2020-2025)
3.1.2 Global Adeno Associated Virus Vector CDMO Revenue Market Share by Players (2020-2025)
3.2 Global Top Adeno Associated Virus Vector CDMO Players by Company Type and Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Adeno Associated Virus Vector CDMO Revenue
3.4 Global Adeno Associated Virus Vector CDMO Market Concentration Ratio
3.4.1 Global Adeno Associated Virus Vector CDMO Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Adeno Associated Virus Vector CDMO Revenue in 2024
3.5 Global Key Players of Adeno Associated Virus Vector CDMO Head office and Area Served
3.6 Global Key Players of Adeno Associated Virus Vector CDMO, Product and Application
3.7 Global Key Players of Adeno Associated Virus Vector CDMO, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Adeno Associated Virus Vector CDMO Breakdown Data by Type
4.1 Global Adeno Associated Virus Vector CDMO Historic Market Size by Type (2020-2025)
4.2 Global Adeno Associated Virus Vector CDMO Forecasted Market Size by Type (2026-2031)
5 Adeno Associated Virus Vector CDMO Breakdown Data by Application
5.1 Global Adeno Associated Virus Vector CDMO Historic Market Size by Application (2020-2025)
5.2 Global Adeno Associated Virus Vector CDMO Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America Adeno Associated Virus Vector CDMO Market Size (2020-2031)
6.2 North America Adeno Associated Virus Vector CDMO Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Adeno Associated Virus Vector CDMO Market Size by Country (2020-2025)
6.4 North America Adeno Associated Virus Vector CDMO Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Adeno Associated Virus Vector CDMO Market Size (2020-2031)
7.2 Europe Adeno Associated Virus Vector CDMO Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Adeno Associated Virus Vector CDMO Market Size by Country (2020-2025)
7.4 Europe Adeno Associated Virus Vector CDMO Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Ireland
8 Asia-Pacific
8.1 Asia-Pacific Adeno Associated Virus Vector CDMO Market Size (2020-2031)
8.2 Asia-Pacific Adeno Associated Virus Vector CDMO Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Adeno Associated Virus Vector CDMO Market Size by Region (2020-2025)
8.4 Asia-Pacific Adeno Associated Virus Vector CDMO Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia & New Zealand
9 Latin America
9.1 Latin America Adeno Associated Virus Vector CDMO Market Size (2020-2031)
9.2 Latin America Adeno Associated Virus Vector CDMO Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Adeno Associated Virus Vector CDMO Market Size by Country (2020-2025)
9.4 Latin America Adeno Associated Virus Vector CDMO Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Adeno Associated Virus Vector CDMO Market Size (2020-2031)
10.2 Middle East & Africa Adeno Associated Virus Vector CDMO Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Adeno Associated Virus Vector CDMO Market Size by Country (2020-2025)
10.4 Middle East & Africa Adeno Associated Virus Vector CDMO Market Size by Country (2026-2031)
10.5 Israel
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Thermo Fisher Scientific
11.1.1 Thermo Fisher Scientific Company Details
11.1.2 Thermo Fisher Scientific Business Overview
11.1.3 Thermo Fisher Scientific Adeno Associated Virus Vector CDMO Introduction
11.1.4 Thermo Fisher Scientific Revenue in Adeno Associated Virus Vector CDMO Business (2020-2025)
11.1.5 Thermo Fisher Scientific Recent Development
11.2 Oxford BioMedica
11.2.1 Oxford BioMedica Company Details
11.2.2 Oxford BioMedica Business Overview
11.2.3 Oxford BioMedica Adeno Associated Virus Vector CDMO Introduction
11.2.4 Oxford BioMedica Revenue in Adeno Associated Virus Vector CDMO Business (2020-2025)
11.2.5 Oxford BioMedica Recent Development
11.3 Lonza
11.3.1 Lonza Company Details
11.3.2 Lonza Business Overview
11.3.3 Lonza Adeno Associated Virus Vector CDMO Introduction
11.3.4 Lonza Revenue in Adeno Associated Virus Vector CDMO Business (2020-2025)
11.3.5 Lonza Recent Development
11.4 GENEWIZ
11.4.1 GENEWIZ Company Details
11.4.2 GENEWIZ Business Overview
11.4.3 GENEWIZ Adeno Associated Virus Vector CDMO Introduction
11.4.4 GENEWIZ Revenue in Adeno Associated Virus Vector CDMO Business (2020-2025)
11.4.5 GENEWIZ Recent Development
11.5 Revvity
11.5.1 Revvity Company Details
11.5.2 Revvity Business Overview
11.5.3 Revvity Adeno Associated Virus Vector CDMO Introduction
11.5.4 Revvity Revenue in Adeno Associated Virus Vector CDMO Business (2020-2025)
11.5.5 Revvity Recent Development
11.6 VectorBuilder
11.6.1 VectorBuilder Company Details
11.6.2 VectorBuilder Business Overview
11.6.3 VectorBuilder Adeno Associated Virus Vector CDMO Introduction
11.6.4 VectorBuilder Revenue in Adeno Associated Virus Vector CDMO Business (2020-2025)
11.6.5 VectorBuilder Recent Development
11.7 OBIO Technology
11.7.1 OBIO Technology Company Details
11.7.2 OBIO Technology Business Overview
11.7.3 OBIO Technology Adeno Associated Virus Vector CDMO Introduction
11.7.4 OBIO Technology Revenue in Adeno Associated Virus Vector CDMO Business (2020-2025)
11.7.5 OBIO Technology Recent Development
11.8 Takara Bio
11.8.1 Takara Bio Company Details
11.8.2 Takara Bio Business Overview
11.8.3 Takara Bio Adeno Associated Virus Vector CDMO Introduction
11.8.4 Takara Bio Revenue in Adeno Associated Virus Vector CDMO Business (2020-2025)
11.8.5 Takara Bio Recent Development
11.9 GenScript Biotech
11.9.1 GenScript Biotech Company Details
11.9.2 GenScript Biotech Business Overview
11.9.3 GenScript Biotech Adeno Associated Virus Vector CDMO Introduction
11.9.4 GenScript Biotech Revenue in Adeno Associated Virus Vector CDMO Business (2020-2025)
11.9.5 GenScript Biotech Recent Development
11.10 Gene Chem
11.10.1 Gene Chem Company Details
11.10.2 Gene Chem Business Overview
11.10.3 Gene Chem Adeno Associated Virus Vector CDMO Introduction
11.10.4 Gene Chem Revenue in Adeno Associated Virus Vector CDMO Business (2020-2025)
11.10.5 Gene Chem Recent Development
11.11 Geno Meditech
11.11.1 Geno Meditech Company Details
11.11.2 Geno Meditech Business Overview
11.11.3 Geno Meditech Adeno Associated Virus Vector CDMO Introduction
11.11.4 Geno Meditech Revenue in Adeno Associated Virus Vector CDMO Business (2020-2025)
11.11.5 Geno Meditech Recent Development
11.12 PackGene Biotech
11.12.1 PackGene Biotech Company Details
11.12.2 PackGene Biotech Business Overview
11.12.3 PackGene Biotech Adeno Associated Virus Vector CDMO Introduction
11.12.4 PackGene Biotech Revenue in Adeno Associated Virus Vector CDMO Business (2020-2025)
11.12.5 PackGene Biotech Recent Development
11.13 VIROVEK
11.13.1 VIROVEK Company Details
11.13.2 VIROVEK Business Overview
11.13.3 VIROVEK Adeno Associated Virus Vector CDMO Introduction
11.13.4 VIROVEK Revenue in Adeno Associated Virus Vector CDMO Business (2020-2025)
11.13.5 VIROVEK Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Adeno Associated Virus Vector CDMO Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 Clinical
1.2.3 Preclinical
1.2.4 Commerical
1.3 Market by Application
1.3.1 Global Adeno Associated Virus Vector CDMO Market Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Pharmaceutical and Biopharmaceutical Companies
1.3.3 Academics and Research Institutes
1.3.4 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Adeno Associated Virus Vector CDMO Market Perspective (2020-2031)
2.2 Global Adeno Associated Virus Vector CDMO Growth Trends by Region
2.2.1 Global Adeno Associated Virus Vector CDMO Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 Adeno Associated Virus Vector CDMO Historic Market Size by Region (2020-2025)
2.2.3 Adeno Associated Virus Vector CDMO Forecasted Market Size by Region (2026-2031)
2.3 Adeno Associated Virus Vector CDMO Market Dynamics
2.3.1 Adeno Associated Virus Vector CDMO Industry Trends
2.3.2 Adeno Associated Virus Vector CDMO Market Drivers
2.3.3 Adeno Associated Virus Vector CDMO Market Challenges
2.3.4 Adeno Associated Virus Vector CDMO Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Adeno Associated Virus Vector CDMO Players by Revenue
3.1.1 Global Top Adeno Associated Virus Vector CDMO Players by Revenue (2020-2025)
3.1.2 Global Adeno Associated Virus Vector CDMO Revenue Market Share by Players (2020-2025)
3.2 Global Top Adeno Associated Virus Vector CDMO Players by Company Type and Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Adeno Associated Virus Vector CDMO Revenue
3.4 Global Adeno Associated Virus Vector CDMO Market Concentration Ratio
3.4.1 Global Adeno Associated Virus Vector CDMO Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Adeno Associated Virus Vector CDMO Revenue in 2024
3.5 Global Key Players of Adeno Associated Virus Vector CDMO Head office and Area Served
3.6 Global Key Players of Adeno Associated Virus Vector CDMO, Product and Application
3.7 Global Key Players of Adeno Associated Virus Vector CDMO, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Adeno Associated Virus Vector CDMO Breakdown Data by Type
4.1 Global Adeno Associated Virus Vector CDMO Historic Market Size by Type (2020-2025)
4.2 Global Adeno Associated Virus Vector CDMO Forecasted Market Size by Type (2026-2031)
5 Adeno Associated Virus Vector CDMO Breakdown Data by Application
5.1 Global Adeno Associated Virus Vector CDMO Historic Market Size by Application (2020-2025)
5.2 Global Adeno Associated Virus Vector CDMO Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America Adeno Associated Virus Vector CDMO Market Size (2020-2031)
6.2 North America Adeno Associated Virus Vector CDMO Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Adeno Associated Virus Vector CDMO Market Size by Country (2020-2025)
6.4 North America Adeno Associated Virus Vector CDMO Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Adeno Associated Virus Vector CDMO Market Size (2020-2031)
7.2 Europe Adeno Associated Virus Vector CDMO Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Adeno Associated Virus Vector CDMO Market Size by Country (2020-2025)
7.4 Europe Adeno Associated Virus Vector CDMO Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Ireland
8 Asia-Pacific
8.1 Asia-Pacific Adeno Associated Virus Vector CDMO Market Size (2020-2031)
8.2 Asia-Pacific Adeno Associated Virus Vector CDMO Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Adeno Associated Virus Vector CDMO Market Size by Region (2020-2025)
8.4 Asia-Pacific Adeno Associated Virus Vector CDMO Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia & New Zealand
9 Latin America
9.1 Latin America Adeno Associated Virus Vector CDMO Market Size (2020-2031)
9.2 Latin America Adeno Associated Virus Vector CDMO Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Adeno Associated Virus Vector CDMO Market Size by Country (2020-2025)
9.4 Latin America Adeno Associated Virus Vector CDMO Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Adeno Associated Virus Vector CDMO Market Size (2020-2031)
10.2 Middle East & Africa Adeno Associated Virus Vector CDMO Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Adeno Associated Virus Vector CDMO Market Size by Country (2020-2025)
10.4 Middle East & Africa Adeno Associated Virus Vector CDMO Market Size by Country (2026-2031)
10.5 Israel
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Thermo Fisher Scientific
11.1.1 Thermo Fisher Scientific Company Details
11.1.2 Thermo Fisher Scientific Business Overview
11.1.3 Thermo Fisher Scientific Adeno Associated Virus Vector CDMO Introduction
11.1.4 Thermo Fisher Scientific Revenue in Adeno Associated Virus Vector CDMO Business (2020-2025)
11.1.5 Thermo Fisher Scientific Recent Development
11.2 Oxford BioMedica
11.2.1 Oxford BioMedica Company Details
11.2.2 Oxford BioMedica Business Overview
11.2.3 Oxford BioMedica Adeno Associated Virus Vector CDMO Introduction
11.2.4 Oxford BioMedica Revenue in Adeno Associated Virus Vector CDMO Business (2020-2025)
11.2.5 Oxford BioMedica Recent Development
11.3 Lonza
11.3.1 Lonza Company Details
11.3.2 Lonza Business Overview
11.3.3 Lonza Adeno Associated Virus Vector CDMO Introduction
11.3.4 Lonza Revenue in Adeno Associated Virus Vector CDMO Business (2020-2025)
11.3.5 Lonza Recent Development
11.4 GENEWIZ
11.4.1 GENEWIZ Company Details
11.4.2 GENEWIZ Business Overview
11.4.3 GENEWIZ Adeno Associated Virus Vector CDMO Introduction
11.4.4 GENEWIZ Revenue in Adeno Associated Virus Vector CDMO Business (2020-2025)
11.4.5 GENEWIZ Recent Development
11.5 Revvity
11.5.1 Revvity Company Details
11.5.2 Revvity Business Overview
11.5.3 Revvity Adeno Associated Virus Vector CDMO Introduction
11.5.4 Revvity Revenue in Adeno Associated Virus Vector CDMO Business (2020-2025)
11.5.5 Revvity Recent Development
11.6 VectorBuilder
11.6.1 VectorBuilder Company Details
11.6.2 VectorBuilder Business Overview
11.6.3 VectorBuilder Adeno Associated Virus Vector CDMO Introduction
11.6.4 VectorBuilder Revenue in Adeno Associated Virus Vector CDMO Business (2020-2025)
11.6.5 VectorBuilder Recent Development
11.7 OBIO Technology
11.7.1 OBIO Technology Company Details
11.7.2 OBIO Technology Business Overview
11.7.3 OBIO Technology Adeno Associated Virus Vector CDMO Introduction
11.7.4 OBIO Technology Revenue in Adeno Associated Virus Vector CDMO Business (2020-2025)
11.7.5 OBIO Technology Recent Development
11.8 Takara Bio
11.8.1 Takara Bio Company Details
11.8.2 Takara Bio Business Overview
11.8.3 Takara Bio Adeno Associated Virus Vector CDMO Introduction
11.8.4 Takara Bio Revenue in Adeno Associated Virus Vector CDMO Business (2020-2025)
11.8.5 Takara Bio Recent Development
11.9 GenScript Biotech
11.9.1 GenScript Biotech Company Details
11.9.2 GenScript Biotech Business Overview
11.9.3 GenScript Biotech Adeno Associated Virus Vector CDMO Introduction
11.9.4 GenScript Biotech Revenue in Adeno Associated Virus Vector CDMO Business (2020-2025)
11.9.5 GenScript Biotech Recent Development
11.10 Gene Chem
11.10.1 Gene Chem Company Details
11.10.2 Gene Chem Business Overview
11.10.3 Gene Chem Adeno Associated Virus Vector CDMO Introduction
11.10.4 Gene Chem Revenue in Adeno Associated Virus Vector CDMO Business (2020-2025)
11.10.5 Gene Chem Recent Development
11.11 Geno Meditech
11.11.1 Geno Meditech Company Details
11.11.2 Geno Meditech Business Overview
11.11.3 Geno Meditech Adeno Associated Virus Vector CDMO Introduction
11.11.4 Geno Meditech Revenue in Adeno Associated Virus Vector CDMO Business (2020-2025)
11.11.5 Geno Meditech Recent Development
11.12 PackGene Biotech
11.12.1 PackGene Biotech Company Details
11.12.2 PackGene Biotech Business Overview
11.12.3 PackGene Biotech Adeno Associated Virus Vector CDMO Introduction
11.12.4 PackGene Biotech Revenue in Adeno Associated Virus Vector CDMO Business (2020-2025)
11.12.5 PackGene Biotech Recent Development
11.13 VIROVEK
11.13.1 VIROVEK Company Details
11.13.2 VIROVEK Business Overview
11.13.3 VIROVEK Adeno Associated Virus Vector CDMO Introduction
11.13.4 VIROVEK Revenue in Adeno Associated Virus Vector CDMO Business (2020-2025)
11.13.5 VIROVEK Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
List of Tables
Table 1. Global Adeno Associated Virus Vector CDMO Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
Table 2. Key Players of Clinical
Table 3. Key Players of Preclinical
Table 4. Key Players of Commerical
Table 5. Global Adeno Associated Virus Vector CDMO Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
Table 6. Global Adeno Associated Virus Vector CDMO Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Table 7. Global Adeno Associated Virus Vector CDMO Market Size by Region (2020-2025) & (US$ Million)
Table 8. Global Adeno Associated Virus Vector CDMO Market Share by Region (2020-2025)
Table 9. Global Adeno Associated Virus Vector CDMO Forecasted Market Size by Region (2026-2031) & (US$ Million)
Table 10. Global Adeno Associated Virus Vector CDMO Market Share by Region (2026-2031)
Table 11. Adeno Associated Virus Vector CDMO Market Trends
Table 12. Adeno Associated Virus Vector CDMO Market Drivers
Table 13. Adeno Associated Virus Vector CDMO Market Challenges
Table 14. Adeno Associated Virus Vector CDMO Market Restraints
Table 15. Global Adeno Associated Virus Vector CDMO Revenue by Players (2020-2025) & (US$ Million)
Table 16. Global Adeno Associated Virus Vector CDMO Market Share by Players (2020-2025)
Table 17. Global Top Adeno Associated Virus Vector CDMO Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Adeno Associated Virus Vector CDMO as of 2024)
Table 18. Ranking of Global Top Adeno Associated Virus Vector CDMO Companies by Revenue (US$ Million) in 2024
Table 19. Global 5 Largest Players Market Share by Adeno Associated Virus Vector CDMO Revenue (CR5 and HHI) & (2020-2025)
Table 20. Global Key Players of Adeno Associated Virus Vector CDMO, Headquarters and Area Served
Table 21. Global Key Players of Adeno Associated Virus Vector CDMO, Product and Application
Table 22. Global Key Players of Adeno Associated Virus Vector CDMO, Date of Enter into This Industry
Table 23. Mergers & Acquisitions, Expansion Plans
Table 24. Global Adeno Associated Virus Vector CDMO Market Size by Type (2020-2025) & (US$ Million)
Table 25. Global Adeno Associated Virus Vector CDMO Revenue Market Share by Type (2020-2025)
Table 26. Global Adeno Associated Virus Vector CDMO Forecasted Market Size by Type (2026-2031) & (US$ Million)
Table 27. Global Adeno Associated Virus Vector CDMO Revenue Market Share by Type (2026-2031)
Table 28. Global Adeno Associated Virus Vector CDMO Market Size by Application (2020-2025) & (US$ Million)
Table 29. Global Adeno Associated Virus Vector CDMO Revenue Market Share by Application (2020-2025)
Table 30. Global Adeno Associated Virus Vector CDMO Forecasted Market Size by Application (2026-2031) & (US$ Million)
Table 31. Global Adeno Associated Virus Vector CDMO Revenue Market Share by Application (2026-2031)
Table 32. North America Adeno Associated Virus Vector CDMO Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 33. North America Adeno Associated Virus Vector CDMO Market Size by Country (2020-2025) & (US$ Million)
Table 34. North America Adeno Associated Virus Vector CDMO Market Size by Country (2026-2031) & (US$ Million)
Table 35. Europe Adeno Associated Virus Vector CDMO Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 36. Europe Adeno Associated Virus Vector CDMO Market Size by Country (2020-2025) & (US$ Million)
Table 37. Europe Adeno Associated Virus Vector CDMO Market Size by Country (2026-2031) & (US$ Million)
Table 38. Asia-Pacific Adeno Associated Virus Vector CDMO Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031
Table 39. Asia-Pacific Adeno Associated Virus Vector CDMO Market Size by Region (2020-2025) & (US$ Million)
Table 40. Asia-Pacific Adeno Associated Virus Vector CDMO Market Size by Region (2026-2031) & (US$ Million)
Table 41. Latin America Adeno Associated Virus Vector CDMO Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 42. Latin America Adeno Associated Virus Vector CDMO Market Size by Country (2020-2025) & (US$ Million)
Table 43. Latin America Adeno Associated Virus Vector CDMO Market Size by Country (2026-2031) & (US$ Million)
Table 44. Middle East & Africa Adeno Associated Virus Vector CDMO Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 45. Middle East & Africa Adeno Associated Virus Vector CDMO Market Size by Country (2020-2025) & (US$ Million)
Table 46. Middle East & Africa Adeno Associated Virus Vector CDMO Market Size by Country (2026-2031) & (US$ Million)
Table 47. Thermo Fisher Scientific Company Details
Table 48. Thermo Fisher Scientific Business Overview
Table 49. Thermo Fisher Scientific Adeno Associated Virus Vector CDMO Product
Table 50. Thermo Fisher Scientific Revenue in Adeno Associated Virus Vector CDMO Business (2020-2025) & (US$ Million)
Table 51. Thermo Fisher Scientific Recent Development
Table 52. Oxford BioMedica Company Details
Table 53. Oxford BioMedica Business Overview
Table 54. Oxford BioMedica Adeno Associated Virus Vector CDMO Product
Table 55. Oxford BioMedica Revenue in Adeno Associated Virus Vector CDMO Business (2020-2025) & (US$ Million)
Table 56. Oxford BioMedica Recent Development
Table 57. Lonza Company Details
Table 58. Lonza Business Overview
Table 59. Lonza Adeno Associated Virus Vector CDMO Product
Table 60. Lonza Revenue in Adeno Associated Virus Vector CDMO Business (2020-2025) & (US$ Million)
Table 61. Lonza Recent Development
Table 62. GENEWIZ Company Details
Table 63. GENEWIZ Business Overview
Table 64. GENEWIZ Adeno Associated Virus Vector CDMO Product
Table 65. GENEWIZ Revenue in Adeno Associated Virus Vector CDMO Business (2020-2025) & (US$ Million)
Table 66. GENEWIZ Recent Development
Table 67. Revvity Company Details
Table 68. Revvity Business Overview
Table 69. Revvity Adeno Associated Virus Vector CDMO Product
Table 70. Revvity Revenue in Adeno Associated Virus Vector CDMO Business (2020-2025) & (US$ Million)
Table 71. Revvity Recent Development
Table 72. VectorBuilder Company Details
Table 73. VectorBuilder Business Overview
Table 74. VectorBuilder Adeno Associated Virus Vector CDMO Product
Table 75. VectorBuilder Revenue in Adeno Associated Virus Vector CDMO Business (2020-2025) & (US$ Million)
Table 76. VectorBuilder Recent Development
Table 77. OBIO Technology Company Details
Table 78. OBIO Technology Business Overview
Table 79. OBIO Technology Adeno Associated Virus Vector CDMO Product
Table 80. OBIO Technology Revenue in Adeno Associated Virus Vector CDMO Business (2020-2025) & (US$ Million)
Table 81. OBIO Technology Recent Development
Table 82. Takara Bio Company Details
Table 83. Takara Bio Business Overview
Table 84. Takara Bio Adeno Associated Virus Vector CDMO Product
Table 85. Takara Bio Revenue in Adeno Associated Virus Vector CDMO Business (2020-2025) & (US$ Million)
Table 86. Takara Bio Recent Development
Table 87. GenScript Biotech Company Details
Table 88. GenScript Biotech Business Overview
Table 89. GenScript Biotech Adeno Associated Virus Vector CDMO Product
Table 90. GenScript Biotech Revenue in Adeno Associated Virus Vector CDMO Business (2020-2025) & (US$ Million)
Table 91. GenScript Biotech Recent Development
Table 92. Gene Chem Company Details
Table 93. Gene Chem Business Overview
Table 94. Gene Chem Adeno Associated Virus Vector CDMO Product
Table 95. Gene Chem Revenue in Adeno Associated Virus Vector CDMO Business (2020-2025) & (US$ Million)
Table 96. Gene Chem Recent Development
Table 97. Geno Meditech Company Details
Table 98. Geno Meditech Business Overview
Table 99. Geno Meditech Adeno Associated Virus Vector CDMO Product
Table 100. Geno Meditech Revenue in Adeno Associated Virus Vector CDMO Business (2020-2025) & (US$ Million)
Table 101. Geno Meditech Recent Development
Table 102. PackGene Biotech Company Details
Table 103. PackGene Biotech Business Overview
Table 104. PackGene Biotech Adeno Associated Virus Vector CDMO Product
Table 105. PackGene Biotech Revenue in Adeno Associated Virus Vector CDMO Business (2020-2025) & (US$ Million)
Table 106. PackGene Biotech Recent Development
Table 107. VIROVEK Company Details
Table 108. VIROVEK Business Overview
Table 109. VIROVEK Adeno Associated Virus Vector CDMO Product
Table 110. VIROVEK Revenue in Adeno Associated Virus Vector CDMO Business (2020-2025) & (US$ Million)
Table 111. VIROVEK Recent Development
Table 112. Research Programs/Design for This Report
Table 113. Key Data Information from Secondary Sources
Table 114. Key Data Information from Primary Sources
Table 115. Authors List of This Report
List of Figures
Figure 1. Adeno Associated Virus Vector CDMO Picture
Figure 2. Global Adeno Associated Virus Vector CDMO Market Size Comparison by Type (2020-2031) & (US$ Million)
Figure 3. Global Adeno Associated Virus Vector CDMO Market Share by Type: 2024 VS 2031
Figure 4. Clinical Features
Figure 5. Preclinical Features
Figure 6. Commerical Features
Figure 7. Global Adeno Associated Virus Vector CDMO Market Size by Application (2020-2031) & (US$ Million)
Figure 8. Global Adeno Associated Virus Vector CDMO Market Share by Application: 2024 VS 2031
Figure 9. Pharmaceutical and Biopharmaceutical Companies Case Studies
Figure 10. Academics and Research Institutes Case Studies
Figure 11. Others Case Studies
Figure 12. Adeno Associated Virus Vector CDMO Report Years Considered
Figure 13. Global Adeno Associated Virus Vector CDMO Market Size (US$ Million), Year-over-Year: 2020-2031
Figure 14. Global Adeno Associated Virus Vector CDMO Market Size, (US$ Million), 2020 VS 2024 VS 2031
Figure 15. Global Adeno Associated Virus Vector CDMO Market Share by Region: 2024 VS 2031
Figure 16. Global Adeno Associated Virus Vector CDMO Market Share by Players in 2024
Figure 17. Global Adeno Associated Virus Vector CDMO Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
Figure 18. The Top 10 and 5 Players Market Share by Adeno Associated Virus Vector CDMO Revenue in 2024
Figure 19. North America Adeno Associated Virus Vector CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 20. North America Adeno Associated Virus Vector CDMO Market Share by Country (2020-2031)
Figure 21. United States Adeno Associated Virus Vector CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 22. Canada Adeno Associated Virus Vector CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 23. Europe Adeno Associated Virus Vector CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 24. Europe Adeno Associated Virus Vector CDMO Market Share by Country (2020-2031)
Figure 25. Germany Adeno Associated Virus Vector CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 26. France Adeno Associated Virus Vector CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 27. U.K. Adeno Associated Virus Vector CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 28. Italy Adeno Associated Virus Vector CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 29. Russia Adeno Associated Virus Vector CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 30. Ireland Adeno Associated Virus Vector CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 31. Asia-Pacific Adeno Associated Virus Vector CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 32. Asia-Pacific Adeno Associated Virus Vector CDMO Market Share by Region (2020-2031)
Figure 33. China Adeno Associated Virus Vector CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 34. Japan Adeno Associated Virus Vector CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 35. South Korea Adeno Associated Virus Vector CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 36. Southeast Asia Adeno Associated Virus Vector CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 37. India Adeno Associated Virus Vector CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 38. Australia & New Zealand Adeno Associated Virus Vector CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 39. Latin America Adeno Associated Virus Vector CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 40. Latin America Adeno Associated Virus Vector CDMO Market Share by Country (2020-2031)
Figure 41. Mexico Adeno Associated Virus Vector CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 42. Brazil Adeno Associated Virus Vector CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 43. Middle East & Africa Adeno Associated Virus Vector CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 44. Middle East & Africa Adeno Associated Virus Vector CDMO Market Share by Country (2020-2031)
Figure 45. Israel Adeno Associated Virus Vector CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 46. Saudi Arabia Adeno Associated Virus Vector CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 47. UAE Adeno Associated Virus Vector CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 48. Thermo Fisher Scientific Revenue Growth Rate in Adeno Associated Virus Vector CDMO Business (2020-2025)
Figure 49. Oxford BioMedica Revenue Growth Rate in Adeno Associated Virus Vector CDMO Business (2020-2025)
Figure 50. Lonza Revenue Growth Rate in Adeno Associated Virus Vector CDMO Business (2020-2025)
Figure 51. GENEWIZ Revenue Growth Rate in Adeno Associated Virus Vector CDMO Business (2020-2025)
Figure 52. Revvity Revenue Growth Rate in Adeno Associated Virus Vector CDMO Business (2020-2025)
Figure 53. VectorBuilder Revenue Growth Rate in Adeno Associated Virus Vector CDMO Business (2020-2025)
Figure 54. OBIO Technology Revenue Growth Rate in Adeno Associated Virus Vector CDMO Business (2020-2025)
Figure 55. Takara Bio Revenue Growth Rate in Adeno Associated Virus Vector CDMO Business (2020-2025)
Figure 56. GenScript Biotech Revenue Growth Rate in Adeno Associated Virus Vector CDMO Business (2020-2025)
Figure 57. Gene Chem Revenue Growth Rate in Adeno Associated Virus Vector CDMO Business (2020-2025)
Figure 58. Geno Meditech Revenue Growth Rate in Adeno Associated Virus Vector CDMO Business (2020-2025)
Figure 59. PackGene Biotech Revenue Growth Rate in Adeno Associated Virus Vector CDMO Business (2020-2025)
Figure 60. VIROVEK Revenue Growth Rate in Adeno Associated Virus Vector CDMO Business (2020-2025)
Figure 61. Bottom-up and Top-down Approaches for This Report
Figure 62. Data Triangulation
Figure 63. Key Executives Interviewed
Table 1. Global Adeno Associated Virus Vector CDMO Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
Table 2. Key Players of Clinical
Table 3. Key Players of Preclinical
Table 4. Key Players of Commerical
Table 5. Global Adeno Associated Virus Vector CDMO Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
Table 6. Global Adeno Associated Virus Vector CDMO Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Table 7. Global Adeno Associated Virus Vector CDMO Market Size by Region (2020-2025) & (US$ Million)
Table 8. Global Adeno Associated Virus Vector CDMO Market Share by Region (2020-2025)
Table 9. Global Adeno Associated Virus Vector CDMO Forecasted Market Size by Region (2026-2031) & (US$ Million)
Table 10. Global Adeno Associated Virus Vector CDMO Market Share by Region (2026-2031)
Table 11. Adeno Associated Virus Vector CDMO Market Trends
Table 12. Adeno Associated Virus Vector CDMO Market Drivers
Table 13. Adeno Associated Virus Vector CDMO Market Challenges
Table 14. Adeno Associated Virus Vector CDMO Market Restraints
Table 15. Global Adeno Associated Virus Vector CDMO Revenue by Players (2020-2025) & (US$ Million)
Table 16. Global Adeno Associated Virus Vector CDMO Market Share by Players (2020-2025)
Table 17. Global Top Adeno Associated Virus Vector CDMO Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Adeno Associated Virus Vector CDMO as of 2024)
Table 18. Ranking of Global Top Adeno Associated Virus Vector CDMO Companies by Revenue (US$ Million) in 2024
Table 19. Global 5 Largest Players Market Share by Adeno Associated Virus Vector CDMO Revenue (CR5 and HHI) & (2020-2025)
Table 20. Global Key Players of Adeno Associated Virus Vector CDMO, Headquarters and Area Served
Table 21. Global Key Players of Adeno Associated Virus Vector CDMO, Product and Application
Table 22. Global Key Players of Adeno Associated Virus Vector CDMO, Date of Enter into This Industry
Table 23. Mergers & Acquisitions, Expansion Plans
Table 24. Global Adeno Associated Virus Vector CDMO Market Size by Type (2020-2025) & (US$ Million)
Table 25. Global Adeno Associated Virus Vector CDMO Revenue Market Share by Type (2020-2025)
Table 26. Global Adeno Associated Virus Vector CDMO Forecasted Market Size by Type (2026-2031) & (US$ Million)
Table 27. Global Adeno Associated Virus Vector CDMO Revenue Market Share by Type (2026-2031)
Table 28. Global Adeno Associated Virus Vector CDMO Market Size by Application (2020-2025) & (US$ Million)
Table 29. Global Adeno Associated Virus Vector CDMO Revenue Market Share by Application (2020-2025)
Table 30. Global Adeno Associated Virus Vector CDMO Forecasted Market Size by Application (2026-2031) & (US$ Million)
Table 31. Global Adeno Associated Virus Vector CDMO Revenue Market Share by Application (2026-2031)
Table 32. North America Adeno Associated Virus Vector CDMO Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 33. North America Adeno Associated Virus Vector CDMO Market Size by Country (2020-2025) & (US$ Million)
Table 34. North America Adeno Associated Virus Vector CDMO Market Size by Country (2026-2031) & (US$ Million)
Table 35. Europe Adeno Associated Virus Vector CDMO Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 36. Europe Adeno Associated Virus Vector CDMO Market Size by Country (2020-2025) & (US$ Million)
Table 37. Europe Adeno Associated Virus Vector CDMO Market Size by Country (2026-2031) & (US$ Million)
Table 38. Asia-Pacific Adeno Associated Virus Vector CDMO Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031
Table 39. Asia-Pacific Adeno Associated Virus Vector CDMO Market Size by Region (2020-2025) & (US$ Million)
Table 40. Asia-Pacific Adeno Associated Virus Vector CDMO Market Size by Region (2026-2031) & (US$ Million)
Table 41. Latin America Adeno Associated Virus Vector CDMO Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 42. Latin America Adeno Associated Virus Vector CDMO Market Size by Country (2020-2025) & (US$ Million)
Table 43. Latin America Adeno Associated Virus Vector CDMO Market Size by Country (2026-2031) & (US$ Million)
Table 44. Middle East & Africa Adeno Associated Virus Vector CDMO Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 45. Middle East & Africa Adeno Associated Virus Vector CDMO Market Size by Country (2020-2025) & (US$ Million)
Table 46. Middle East & Africa Adeno Associated Virus Vector CDMO Market Size by Country (2026-2031) & (US$ Million)
Table 47. Thermo Fisher Scientific Company Details
Table 48. Thermo Fisher Scientific Business Overview
Table 49. Thermo Fisher Scientific Adeno Associated Virus Vector CDMO Product
Table 50. Thermo Fisher Scientific Revenue in Adeno Associated Virus Vector CDMO Business (2020-2025) & (US$ Million)
Table 51. Thermo Fisher Scientific Recent Development
Table 52. Oxford BioMedica Company Details
Table 53. Oxford BioMedica Business Overview
Table 54. Oxford BioMedica Adeno Associated Virus Vector CDMO Product
Table 55. Oxford BioMedica Revenue in Adeno Associated Virus Vector CDMO Business (2020-2025) & (US$ Million)
Table 56. Oxford BioMedica Recent Development
Table 57. Lonza Company Details
Table 58. Lonza Business Overview
Table 59. Lonza Adeno Associated Virus Vector CDMO Product
Table 60. Lonza Revenue in Adeno Associated Virus Vector CDMO Business (2020-2025) & (US$ Million)
Table 61. Lonza Recent Development
Table 62. GENEWIZ Company Details
Table 63. GENEWIZ Business Overview
Table 64. GENEWIZ Adeno Associated Virus Vector CDMO Product
Table 65. GENEWIZ Revenue in Adeno Associated Virus Vector CDMO Business (2020-2025) & (US$ Million)
Table 66. GENEWIZ Recent Development
Table 67. Revvity Company Details
Table 68. Revvity Business Overview
Table 69. Revvity Adeno Associated Virus Vector CDMO Product
Table 70. Revvity Revenue in Adeno Associated Virus Vector CDMO Business (2020-2025) & (US$ Million)
Table 71. Revvity Recent Development
Table 72. VectorBuilder Company Details
Table 73. VectorBuilder Business Overview
Table 74. VectorBuilder Adeno Associated Virus Vector CDMO Product
Table 75. VectorBuilder Revenue in Adeno Associated Virus Vector CDMO Business (2020-2025) & (US$ Million)
Table 76. VectorBuilder Recent Development
Table 77. OBIO Technology Company Details
Table 78. OBIO Technology Business Overview
Table 79. OBIO Technology Adeno Associated Virus Vector CDMO Product
Table 80. OBIO Technology Revenue in Adeno Associated Virus Vector CDMO Business (2020-2025) & (US$ Million)
Table 81. OBIO Technology Recent Development
Table 82. Takara Bio Company Details
Table 83. Takara Bio Business Overview
Table 84. Takara Bio Adeno Associated Virus Vector CDMO Product
Table 85. Takara Bio Revenue in Adeno Associated Virus Vector CDMO Business (2020-2025) & (US$ Million)
Table 86. Takara Bio Recent Development
Table 87. GenScript Biotech Company Details
Table 88. GenScript Biotech Business Overview
Table 89. GenScript Biotech Adeno Associated Virus Vector CDMO Product
Table 90. GenScript Biotech Revenue in Adeno Associated Virus Vector CDMO Business (2020-2025) & (US$ Million)
Table 91. GenScript Biotech Recent Development
Table 92. Gene Chem Company Details
Table 93. Gene Chem Business Overview
Table 94. Gene Chem Adeno Associated Virus Vector CDMO Product
Table 95. Gene Chem Revenue in Adeno Associated Virus Vector CDMO Business (2020-2025) & (US$ Million)
Table 96. Gene Chem Recent Development
Table 97. Geno Meditech Company Details
Table 98. Geno Meditech Business Overview
Table 99. Geno Meditech Adeno Associated Virus Vector CDMO Product
Table 100. Geno Meditech Revenue in Adeno Associated Virus Vector CDMO Business (2020-2025) & (US$ Million)
Table 101. Geno Meditech Recent Development
Table 102. PackGene Biotech Company Details
Table 103. PackGene Biotech Business Overview
Table 104. PackGene Biotech Adeno Associated Virus Vector CDMO Product
Table 105. PackGene Biotech Revenue in Adeno Associated Virus Vector CDMO Business (2020-2025) & (US$ Million)
Table 106. PackGene Biotech Recent Development
Table 107. VIROVEK Company Details
Table 108. VIROVEK Business Overview
Table 109. VIROVEK Adeno Associated Virus Vector CDMO Product
Table 110. VIROVEK Revenue in Adeno Associated Virus Vector CDMO Business (2020-2025) & (US$ Million)
Table 111. VIROVEK Recent Development
Table 112. Research Programs/Design for This Report
Table 113. Key Data Information from Secondary Sources
Table 114. Key Data Information from Primary Sources
Table 115. Authors List of This Report
List of Figures
Figure 1. Adeno Associated Virus Vector CDMO Picture
Figure 2. Global Adeno Associated Virus Vector CDMO Market Size Comparison by Type (2020-2031) & (US$ Million)
Figure 3. Global Adeno Associated Virus Vector CDMO Market Share by Type: 2024 VS 2031
Figure 4. Clinical Features
Figure 5. Preclinical Features
Figure 6. Commerical Features
Figure 7. Global Adeno Associated Virus Vector CDMO Market Size by Application (2020-2031) & (US$ Million)
Figure 8. Global Adeno Associated Virus Vector CDMO Market Share by Application: 2024 VS 2031
Figure 9. Pharmaceutical and Biopharmaceutical Companies Case Studies
Figure 10. Academics and Research Institutes Case Studies
Figure 11. Others Case Studies
Figure 12. Adeno Associated Virus Vector CDMO Report Years Considered
Figure 13. Global Adeno Associated Virus Vector CDMO Market Size (US$ Million), Year-over-Year: 2020-2031
Figure 14. Global Adeno Associated Virus Vector CDMO Market Size, (US$ Million), 2020 VS 2024 VS 2031
Figure 15. Global Adeno Associated Virus Vector CDMO Market Share by Region: 2024 VS 2031
Figure 16. Global Adeno Associated Virus Vector CDMO Market Share by Players in 2024
Figure 17. Global Adeno Associated Virus Vector CDMO Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
Figure 18. The Top 10 and 5 Players Market Share by Adeno Associated Virus Vector CDMO Revenue in 2024
Figure 19. North America Adeno Associated Virus Vector CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 20. North America Adeno Associated Virus Vector CDMO Market Share by Country (2020-2031)
Figure 21. United States Adeno Associated Virus Vector CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 22. Canada Adeno Associated Virus Vector CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 23. Europe Adeno Associated Virus Vector CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 24. Europe Adeno Associated Virus Vector CDMO Market Share by Country (2020-2031)
Figure 25. Germany Adeno Associated Virus Vector CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 26. France Adeno Associated Virus Vector CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 27. U.K. Adeno Associated Virus Vector CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 28. Italy Adeno Associated Virus Vector CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 29. Russia Adeno Associated Virus Vector CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 30. Ireland Adeno Associated Virus Vector CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 31. Asia-Pacific Adeno Associated Virus Vector CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 32. Asia-Pacific Adeno Associated Virus Vector CDMO Market Share by Region (2020-2031)
Figure 33. China Adeno Associated Virus Vector CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 34. Japan Adeno Associated Virus Vector CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 35. South Korea Adeno Associated Virus Vector CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 36. Southeast Asia Adeno Associated Virus Vector CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 37. India Adeno Associated Virus Vector CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 38. Australia & New Zealand Adeno Associated Virus Vector CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 39. Latin America Adeno Associated Virus Vector CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 40. Latin America Adeno Associated Virus Vector CDMO Market Share by Country (2020-2031)
Figure 41. Mexico Adeno Associated Virus Vector CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 42. Brazil Adeno Associated Virus Vector CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 43. Middle East & Africa Adeno Associated Virus Vector CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 44. Middle East & Africa Adeno Associated Virus Vector CDMO Market Share by Country (2020-2031)
Figure 45. Israel Adeno Associated Virus Vector CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 46. Saudi Arabia Adeno Associated Virus Vector CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 47. UAE Adeno Associated Virus Vector CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 48. Thermo Fisher Scientific Revenue Growth Rate in Adeno Associated Virus Vector CDMO Business (2020-2025)
Figure 49. Oxford BioMedica Revenue Growth Rate in Adeno Associated Virus Vector CDMO Business (2020-2025)
Figure 50. Lonza Revenue Growth Rate in Adeno Associated Virus Vector CDMO Business (2020-2025)
Figure 51. GENEWIZ Revenue Growth Rate in Adeno Associated Virus Vector CDMO Business (2020-2025)
Figure 52. Revvity Revenue Growth Rate in Adeno Associated Virus Vector CDMO Business (2020-2025)
Figure 53. VectorBuilder Revenue Growth Rate in Adeno Associated Virus Vector CDMO Business (2020-2025)
Figure 54. OBIO Technology Revenue Growth Rate in Adeno Associated Virus Vector CDMO Business (2020-2025)
Figure 55. Takara Bio Revenue Growth Rate in Adeno Associated Virus Vector CDMO Business (2020-2025)
Figure 56. GenScript Biotech Revenue Growth Rate in Adeno Associated Virus Vector CDMO Business (2020-2025)
Figure 57. Gene Chem Revenue Growth Rate in Adeno Associated Virus Vector CDMO Business (2020-2025)
Figure 58. Geno Meditech Revenue Growth Rate in Adeno Associated Virus Vector CDMO Business (2020-2025)
Figure 59. PackGene Biotech Revenue Growth Rate in Adeno Associated Virus Vector CDMO Business (2020-2025)
Figure 60. VIROVEK Revenue Growth Rate in Adeno Associated Virus Vector CDMO Business (2020-2025)
Figure 61. Bottom-up and Top-down Approaches for This Report
Figure 62. Data Triangulation
Figure 63. Key Executives Interviewed
Our team would be happy to assist you with your queries.
About us
Accurate data, The latest market trends, And deeper research directions.
Our sole purpose is to provide a basis for leaders in all walks of life to make more appropriate decisions, to help companies solve existing problems and achieve business goals
Latest reports
Global Benzyltrimethylammonium Hydroxide (BTMAH) Market Research Report 2025
Jul 10, 25
Global Allyltrimethylammonium Chloride Market Research Report 2025
Jul 10, 25
Global Calcium Bisglycinate Market Research Report 2025
Jul 10, 25
Useful links
Our Contacts
Room 2306, T6 Fuxing World Financial Center, Kaifu District, Changsha, Hunan, China
(+86) 159 1069 5232